RNUGF
Price:
$0.0011
Market Cap:
$47.12K
ReNeuron Group plc researches, develops, and commercializes cell-based therapies in the United Kingdom. The company engages in the development of CTX stem cell therapy candidate for treating stroke disability; and human retinal progenitor cell therapy that is in Phase 2 clinical trial for treating retinitis pigmentosa, a blindness-causing disease. It also develops CTX-derived exosomes that are in the pre-clinical stage, which are Nano-sized packages of information released by CTX cells. In addition, the company licenses ReNcell products. It has a collaboration agreement with University College London to conduct research into the generation of immune cells from induced pluripotent stem cells ...[Read more]
Industry
Biotechnology
IPO Date
2007-04-12
Stock Exchange
OTC
Ticker
RNUGF
According to ReNeuron Group plc’s latest financial reports and current stock price. The company's current ROE is -72.37%. This represents a change of 15.16% compared to the average of -62.85% of the last 4 quarters.
The mean historical ROE of ReNeuron Group plc over the last ten years is -60.67%. The current -72.37% ROE has changed 19.28% with respect to the historical average. Over the past ten years (40 quarters), RNUGF's ROE was at its highest in in the March 2005 quarter at 159.42%. The ROE was at its lowest in in the September 2004 quarter at -237.37%.
Average
-60.67%
Median
-60.53%
Minimum
-106.94%
Maximum
-16.78%
Discovering the peaks and valleys of ReNeuron Group plc ROE, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.
Maximum Annual Increase = 108.38%
Maximum Annual ROE = -16.78%
Minimum Annual Increase = -75.25%
Minimum Annual ROE = -106.94%
| Year | ROE | Change |
|---|---|---|
| 2023 | -106.94% | 9.14% |
| 2022 | -97.99% | 63.25% |
| 2021 | -60.02% | -30.45% |
| 2020 | -86.30% | 41.41% |
| 2019 | -61.03% | 27.05% |
| 2018 | -48.04% | 63.97% |
| 2017 | -29.30% | 74.58% |
| 2016 | -16.78% | -75.25% |
| 2015 | -67.80% | 108.38% |
| 2014 | -32.54% | -74.83% |
The current ROE of ReNeuron Group plc (RNUGF) is greater than its 3-year, greater than its 5-year, and greater than its 10-year historical averages
3-year avg
-88.32%
5-year avg
-82.46%
10-year avg
-60.67%
ReNeuron Group plc’s ROE is less than Ayala Pharmaceuticals, Inc. (12.17%), greater than Algernon Pharmaceuticals Inc. (-98.85%), less than Appili Therapeutics Inc. (16.72%), greater than Universal Ibogaine Inc. (-304.82%), less than Restart Life Sciences Corp. (404.52%), less than AXIM Biotechnologies, Inc. (34.02%), less than VG Life Sciences Inc. (0%), less than America Great Health (20.07%), less than Regen BioPharma, Inc. (17.33%), less than Health Sciences Group, Inc. (2.53%),
| Company | ROE | Market cap |
|---|---|---|
| 12.17% | $4.41M | |
| -98.85% | $1.92M | |
| 16.72% | $1.82M | |
| -304.82% | $2.06M | |
| 404.52% | $2.27M | |
| 34.02% | $7.33M | |
| 0% | $2.11M | |
| 20.07% | $2.12M | |
| 17.33% | $315.55K | |
| 2.53% | $187.09K |
One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like ReNeuron Group plc using the financials and key metrics that matter to you in a single view.
The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:
Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.
Get your free trial here.
The easiest way to analyze a company like ReNeuron Group plc or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.
Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.
Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.
What is the ROE?
How can you use the ROE?
What is ReNeuron Group plc's ROE?
How is the ROE calculated for ReNeuron Group plc (RNUGF)?
What is the highest ROE for ReNeuron Group plc (RNUGF)?
What is the 3-year average ROE for ReNeuron Group plc (RNUGF)?
What is the 5-year average ROE for ReNeuron Group plc (RNUGF)?
How does the current ROE for ReNeuron Group plc (RNUGF) compare to its historical average?